Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors

1 Jan 2014

Abstract excerpt

The recombinant adeno-associated virus (rAAV) gene delivery system is entering a crucial and exciting phase with the promise of more than 20 years of intense research now realized in a number of successful human clinical trials. However, as a natural host to AAV infection, anti-AAV antibodies are prevalent in the human population. For example, ~70% of human sera samples are positive for AAV serotype 2 (AAV2)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to RNA Interference and Gene Delivery
Share to Viral Infections and Immunology Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24523720
DOI: 10.3389/fimmu.2014.00009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery VectorsPMID 24523720Read ↗

Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.Semantic proximity Read ↗

Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehiclesSemantic proximity Read ↗

Structural characterization of antibody-responses following Zolgensma treatment for AAV capsid engineering to expand patient cohortsSemantic proximity Read ↗

Adeno-Associated Virus Structural Biology as a Tool in Vector DevelopmentSemantic proximity Read ↗

High-Resolution Structural Characterization of a New Adeno-associated Virus Serotype 5 Antibody Epitope toward Engineering Antibody-Resistant Recombinant Gene Delivery VectorsSemantic proximity Read ↗

Structural characterization of antibody-responses from Zolgensma treatment provides the blueprint for the engineering of an AAV capsid suitable for redosingSemantic proximity Read ↗

Capsid Antibodies to Different Adeno-Associated Virus Serotypes Bind Common RegionsSemantic proximity Read ↗

AAV Hybrid Serotypes: Improved Vectors for Gene DeliverySemantic proximity Read ↗

Mapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8Semantic proximity Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasionSemantic proximity Read ↗

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.